Celgosivir. Anti-hepatitis C virus drug, α-glucosidase inhibitor

Drugs of the Future

Volumn 30, Issue 6, 2005, Pages 545-552

  Sorbera, L A ^a   Castaner J ^a   Garcia Capdevila L ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

3 [2 [(2 TERT BUTYLPHENYLAMINOOXALYL)AMINO]PROPIONYLAMINO] 4 OXO 5 (2,3,5,6 TETRAFLUOROPHENOXY)PENTANOIC ACID; ALPHA GLUCOSIDASE INHIBITOR; ANTIVIRUS AGENT; BCL 2125; BCL 2329; BCL2329; CASTANOSPERMINE; CASTANOSPERMINE 6 BUTYRATE; CASTANOSPERMINE DERIVATIVE; CILUPREVIR; DIDANOSINE; EMIVIRINE; HCV 796; JTK 003; LOPERAMIDE; MERIMEPODIB; NEVIRAPINE; R 1626; RECOMBINANT ALPHA INTERFERON; RIBAMIDINE; RIBAVIRIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; SUCRASE; T 1106; UNCLASSIFIED DRUG; VALOPICITABINE; VX 950; XTL 2125; XTL 2329; ZALCITABINE; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BOVINE DIARRHEA VIRUS; CLINICAL TRIAL; CONCENTRATION RESPONSE; CYTOTOXICITY; DIARRHEA; DISEASE SEVERITY; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG EFFICACY; DRUG METABOLISM; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; DRUG UPTAKE; ENZYME INHIBITION; FLATULENCE; GASTROINTESTINAL SYMPTOM; HEPATITIS C; HEPATITIS C VIRUS; HERPES SIMPLEX VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IC 50; IN VITRO STUDY; IN VIVO STUDY; LIVER TOXICITY; MAXIMUM TOLERATED DOSE; MULTICENTER STUDY; NONHUMAN; VIRUS CELL INTERACTION;

EID: 23744436074     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2005.030.06.914820     Document Type: Article

References (46)

1. Liu, P.S., Daniel, J.K., Rhinehart, B.L (Aventis Pharma US, Inc.). Castanospermine esters and glycosides. AU 8818448, EP 0297534, JP 1989079179.
2. Anderson, W.K., Coburn, R.A., Gopalsamy, A., Howe, T.J. A facile selective acylation of castanospermine. Tetrahedron Lett 1990, 31: 169-70.
3. Liu, P.J., Hoekstra, W.J., King, C.-H.R. Synthesis of potent anti-HIV agents: Esters of castanospermine. Tetrahedron Lett 1990, 31: 2829-32.
4. Margolin, A.L., Delinck, D.L., Whalon, M.R. Enzyme-catalyzed regioselective acylation of castanospermine. J Am Chem Soc 1990, 112: 2849-54.
5. Goralski, C.T., Stolz-Dunn, S., Louks, D.H., Scherzer, B.D., Nitz, M.A., Smit, M.R. (Aventis Pharma US, Inc.). Process for preparing 6-O-monoesters of castanospermine. CA 2485323, EP 0983270, JP 2002502374, WO 1998052947.
6. Goralski, C.T., Stolz-Dunn, S.K., Hitt, J.E., Louks, D.H., Scherzer, B.D., Nitz, M.A. (Aventis Pharma US, Inc.). Process for preparing 6-O-monoesters of castanospermine. US 5959111.
7. Prous Science Drug R&D Backgrounders: Hepatitis C (online publication). Updated May 12, 2005.
8. WHO 2000. Hepatitis C. WHO Fact Sheet Number 164.
9. Flamm, S.L. Chronic hepatitis C virus infection. JAMA - J Am Med Assoc 2003, 289: 2413-7.
10. Ellgaard, L., Molinari, M., Helenius, A. Setting the standards: Quality control in the secretory pathway. Science 1999, 286: 1882-8.
11. Helenius, A., Aebi, M. Intracellular functions of N-linked glycans. Science 2001, 291: 2364-9.
12. Taylor, D.L., Kang, M.S., Brennan, T.M., Bridges, C.G., Sunkara, P.S., Tyms, A.S. Inhibition of alpha-glucosidase I of the glycoprotein-processing enzymes by 6-O-butanoyl castanospermine (MDL 28,574) and its consequences in human immunodeficiency virus-infected T cells. Antimicrob Agents Chemother 1994, 38: 1780-7.
13. Ahmed, S.P., Nash, R.J., Bridges, C.G., Taylor, D.L., Kang, M.S., Porter, E.A., Tyms, A.S. Antiviral activity and metabolism of the castanospermine derivative MDL 28,574, in cells infected with herpes simplex virus type 2. Biochem Biophys Res Commun 1995, 208: 267-73.
14. Stuyver, L.J., Whitaker, T., McBrayer, T.R. et al. Ribonucleoside analogue that blocks replication of bovine viral diarrhea and hepatitis C viruses in culture. Antimicrob Agents Chemother 2003, 47: 244-54.
15. Pan, Y.T., Ghidoni, J., Elbein, A.D. The effects of castanospermine and swainsonine on the activity and synthesis of intestinal sucrase. Arch Biochem Biophys 1993, 303: 134-44.
16. Taylor, D.L., Sunkara, P.S., Liu, P.S., Kang, M.S., Bowlin, T.L., Tyms, A.S. 6-O-Butanoylcastanospermine (MDL 28,574) inhibits glycoprotein processing and the growth of HIVs. AIDS 1991, 5: 693-8.
17. Migenix reports third quarter fiscal year 2005 results. Migenix Press Release March 10, 2005.
18. Kang, M.S., Liu, P.S., Bernotas, B.C., Harry, B.S., Sunkara, P.S. Castanospermine analogues: Their inhibition of glycoprotein processing alpha-glucosidases from porcine kidney and B16F10 cells. Glycobiology 1995, 5: 147-52.
19. Bridges, C.G., Brennan, T.M., Taylor, D.L., McPherson, M., Tyms, A.S. The prevention of cell adhesion and the cell-to-cell spread of HIV-1 in vitro by the alpha-glucosidase 1 inhibitor, 6-O-butanoyl castanospermine (MDL 28574). Antivir Res 1994, 25: 169-75.
20. Bridges, C.G., Taylor, D.L., Kang, M.S., Brennan, T.M., Tyms, A.S. Treatment with the alpha-glucosidase 1 inhibitor 6-O-butanoyl castanospermine reduces the detection of LFA-1 (CD18/CD11a) by monoclonal antibodies. Glycobiology 1995, 5: 243-7.
21. Brennan, T.M., Taylor, D.L., Bridges, C.G., Leyda, J.P., Tyms, A.S. The inhibition of human immunodeficiency virus type 1 in vitro by a non-nucleoside reverse transcriptase inhibitor MKC-442, alone and in combination with other anti-HIV compounds. Antivir Res 1995, 26: 173-87.
22. Taylor, D.L., Brennan, T.M., Bridges, C.G., Kang, M.S., Tyms, A.S. Synergistic inhibition of human immunodeficiency virus type 1 in vitro by 6-O-butanoylcastanospermine (MDL 28 574) in combination with inhibitors of the virus-encoded reverse transcriptase and proteinase. Antivir Chem Chemother 1995, 6: 143-52.
23. Bridges, C.G., Ahmed, S.P., Kang, M.S., Nash, R.J., Porter, E.A., Tyms, A.S. The effect of oral treatment with 6-O-butanoyl castanospermine (MDL 28,574) in the murine zosteriform model of HSV-1 infection. Glycobiology 1995, 5: 249-53.
24. Whitby, K., Taylor, D., Patel, D., Ahmed, P., Tyms, A.S. Action of celgosivir (6 O-butanoyl castanospermine) against the pestivirus BVDV: Implications for the treatment of hepatitis C. Antivir Chem Chemother 2004, 15: 141-51.
25. Dugourd, D., Siu, R., Fenn, J., Clement, J.J., Coulson, R. Synergistic inhibition of Flaviridae virus by celgosivir in combination with ribavirin or interferon-alpha. 18th Int Conf Antivir Res (April 11-14, Barcelona) 2005, Abst 101.
26. Dugourd, D., Fenn, J., Siu, R., Clement, J.J., Coulson, R. In vitro characterization of celgosivir, a clinical stage compound for the treatment of hepatitis C viral infections. 18th Int Conf Antivir Res (April 11-14, Barcelona) 2005, Abst 105.
27. Kang, M.S. Uptake and metabolism of BuCast: A glycoprotein processing inhibitor and a potential anti-HIV drug. Glycobiology 1996, 6: 209-16.
28. Chang, J., Scott, D.O., Wilson, D.D., Broward, S.M., Ho, J.C., Zadjura, L., Stuhler, J.D., Rose, J.Q. Pharmacokinetics of the glucosidase inhibitor MDL 28, 574 (Bucast) and its active metabolite, MDL 26,190 (castanospermine) in rats and dogs. Pharm Res 1995, 12(9, Suppl.): Abst PPDM 8057.
29. Erfle, D., Rubinchik, E., Pasetka, C., Friedland, H.D., Clement, J.J. Pharmacokinetics of celgosivir (MX-3253), a novel alpha-glucosidase-1 inhibitor, in loperamide-treated and diarrhoea-induced rats. 18th Int Conf Antivir Res (April 11-14, Barcelona) 2005, Abst 103.
30. Stoltz, M.L., McPherson, M., Frampton, M., Sidarous, E., Jacobs, M., Roth, H. Pharmacokinetics of castanospermine in asymptomatic HIV-positive patients treated with MDL 28,574A during phase I trials. 11th Int Conf AIDS (July 7-12, Vancouver) 1996, Abst Mo.B.1329.
31. Roth, H., McPherson, M., Hamedani, P., Herrmann, W.M., Sidarous, E., Frampton, M., Maddern, J., Dieterich, A. Phase I tolerance and pharmacokinetics of a new castanospermine derivative, MDL 28,574A. 11th Int Conf AIDS (July 7-12, Vancouver) 1996, Abst Tu.B.2117.
32. Richmond, G.J., Zolnouni, P., Stall, J., McPherson, M., Hamedani, P., Cross, V., Sidarous, E., Stoltz, M. Efficacy and safety of MDL 28,574A in HIV-positive patients with baseline CD4 values of 301-500. 11th Int Conf AIDS (July 7-12, Vancouver) 1996, Abst Mo.B.1145.
33. Zolmouni, P., Berger, D.S., Perez, G., Hamedani, P., Frampton, M., Gibson, C., Sidarous, E., Stoltz, M. Efficacy and safety of MDL 28.574A in HIV-positive patients with baseline CD4 values of 100-300. 11th Int Conf AIDS (July 7-12, Vancouver) 1996, Abst Mo.B.1138.
34. Arasteh, K., Czerwinska, R., Schlote, F., Fätkenheuer, G., Jessen, H., Moll, A., Gehring, P., Ulmer, A., Hamedani, P., McPherson, M. A randomized, double-blind, dose-ranging phase II European study of the safety and efficacy of chronically administered butanoyl-castanospermine (MDL 28,574A) HIV-infected patients. 11th Int Conf AIDS (July 7-12, Vancouver) 1996, Abst Mo.B.1121.
35. Sunkara, P.S., Taylor, D.L., Kang, M.S., Bowlin, T.L., Liu, P.S., Tyms, A.S., Sjoerdsma, A. Anti-HIV activity of castanospermine analogues. Lancet 1989, 1: 1206.
36. Scott, D.O., Ho, J.C., Chang, J., Wilson, D.D. Validation of a method based on liquid chromatography for the determination of MDL 26,190 (castanospermine) and MDL 28,574 in rat plasma. Pharm Res 1995, 12(9, Suppl.): Abst APQ 1118.
37. Bridges, C.G., Brennan, T.M., Taylor, D.L., McPherson, M., Tyms, A.S. Prevention of cell-to-cell spread of HIV in vitro by the alpha-glucosidase 1 inhibitor, 6-O-butanoyl castanospermine (MDL 28574). 12th Eur Immunol Meet (June 14-17, Barcelona) 1994, 433.
38. Brennan, T.M., Taylor, D.L., Bridges, C.G., Kang, M.S., Tyms, A.S. Two and three-drug synergistic inhibition of human immunodeficiency virus type 1 in vitro by 6-O-butanoylcastanospermine (MDL 28574), in combination with inhibitors of the HIV reverse transcriptase and proteinase. J Cell Biochem - Suppl 1994, 18(PartB): Abst J 501.
39. Tyms, A.S. Natural products in antiviral chemotherapy - New developments. 53rd Int Gong Pharmaceut Sci (Sept 6-10, Tokyo) 1993, Abst B3-19.
40. Kang, M.S., Taylor, D.L., Liu, P.S., Sunkara, P.S., Tyms, A.S. Development of butyryl castanospermine (MDL 28,574) as an antiviral drug. J Cell Biochem - Suppl 1993, 17(Part A): 364.
41. Wright, P.S., Cross-Doersen, D.E., McCann, P.P., Bitonti, A.J. Inhibitors of glycoprotein processing disrupt cytoadherence of plasmodium falciparum-infected erythrocytes with human melanoma cells. FASEB J 1990, 4(7): Abst 550.
42. Taylor, D., Brennan, T., Kang, M., Bridges, G., Sunkara, P., Tyms, S. Specific inhibition of alpha-glucosidase I of the glycoprotein processing enzymes in HIV infected cells by 6-O-butanoyl castanospermine (MDL 28574). J Cell Biochem - Suppl 1992, 16(Part E): Abst Q 556.
43. Kang, M., Ahmed, P., Tyms, S. Effect of alpha-glucosidase 1 inhibition on herpes simplex virus (HSV) glycoprotein synthesis and virus growth in vitro. J Cell Biochem - Suppl 1993, 17(Part A): 382.
44. Ruprecht, R.M., Bernard, L.D., Bronson, R., Gama Sosa, M.A., Mullaney, S. Castanospermine vs. its 6-O-butanoyl analog: A comparison of toxicity and antiviral activity in vitro and in vivo. J Acquir Immune Defic Syndr 1991, 4: 48-55.
45. Gill, H.S. Synthesis of carbon-14 labeled anti-HIV agent 6-O-butyrylcastanospermine. J Label Compd Radiopharm 1998, 41: 201-10.
46. Gill, H.S. Carbon-14 labeled polyhydroxyindolizidines: Synthesis of carbon-14 labeled castanospermine and anti-HIV agent 6-O-butyrylcastanospermine hydrochloride (MDL 28574A). In: Synthesis and Applications of Isotopically Labeled Compounds, J.R. Heys and D.G. Melillo (Eds.), John Wiley & Sons Ltd., 1997, 363-6.